Stock of the Day

February 12, 2021

Aldeyra Therapeutics (ALDX)

$1.48
-$0.01 (-0.3%)
Market Cap: $89.58M

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Today's Trend

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is trading under pressure as investors digest a steady stream of securities class-action notices ahead of a key lead-plaintiff deadline on May 29, 2026. The repeated legal alerts are likely weighing on sentiment because they highlight allegations of investor harm tied to purchases made between November 3, 2023 and March 16, 2026.

  • A class action lawsuit has been filed against Aldeyra Therapeutics and certain officers, with multiple firms urging shareholders who suffered losses to seek lead-plaintiff status before the May 29 deadline. Article Title
  • Rosen Law Firm, Pomerantz, Schall, Faruqi & Faruqi, and other firms continue to publicize the securities-fraud case and deadline, keeping legal overhang in focus for ALDX. Article Title
  • Short-interest data showed no meaningful change, so there is no additional evidence from positioning alone to explain a major move in the shares.

Overall, ALDX appears to be moving lower mainly because of the ongoing class-action headlines and near-term deadline-related uncertainty rather than new operating news.

← Previous Stock of the DayNext Stock of the Day →